Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now?
Open accessThe DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index; 74 of the 94 sources its claims cite were checked for support.
Abstract
Introduction: Although antimicrobials have traditionally been used to treat infections and improve health outcomes, resistance to commonly used antimicrobials has posed a major challenge. An estimated 700,000 deaths occur globally every year as a result of infections caused by antimicrobial-resistant pathogens. Antimicrobial resistance (AMR) also contributes directly to the decline in the global economy. In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions. Methods: We searched PubMed for articles relevant to AMR in pathogens in the WHO-GLASS list and in other infections of local importance in SSA. In this review, we focused on AMR rates and surveillance of AMR for these priority pathogens and some of the most encountered pathogens of public health significance. In addition, we reviewed the implementation of national action plans to mitigate against AMR in countries in SSA. Results and Discussion: The SSA region is disproportionately affected by AMR, in part owing to the prevailing high levels of poverty, which result in a high burden of infectious diseases, poor regulation of antimicrobial use, and a lack of alternatives to ineffective antimicrobials. The global action plan as a strategy for prevention and combating AMR has been adopted by most countries, but fewer countries are able to fully implement country-specific action plans, and several challenges exist in many settings. Conclusion: A concerted One Health approach will be required to ramp up implementation of action plans in the region. In addition to AMR surveillance, effective implementation of infection prevention and control, water, sanitation, and hygiene, and antimicrobial stewardship programs will be key cost-effective strategies in helping to tackle AMR.
Overview
CoChat Summary
TL;DR
This review summarizes antimicrobial resistance rates among WHO-GLASS and locally important pathogens in sub-Saharan Africa and assesses national action plan implementation. It reports that SSA has the highest AMR-attributable mortality and that NAP implementation remains limited by funding, surveillance, and multisectoral coordination gaps.
Key findings
- In 2019, SSA had the highest AMR-attributable mortality rate (23.5 deaths per 100,000), with Western SSA highest at 27.3 deaths per 100,000; globally, 4.95 million deaths were associated with AMR and 1.27 million were attributable to AMR.
- Resistance was widespread among reviewed pathogens: diarrheagenic E. coli prevalence ranged from 14.7% to 82%; multidrug-resistant S. Typhi subclade 4.3.1 prevalence ranged from 60.4% to 97%; MRSA prevalence ranged from 1.25% to 53.4%; carbapenem-resistant P. aeruginosa prevalence ranged from 6% to 34.8%; and East Africa had the highest A. baumannii carbapenem resistance prevalence at 23%.
- NAP implementation was limited: 11 (25%) of 44 SSA countries had NAPs on AMR; 32% performed routine AMR surveillance on clinical pathogens and 2% on veterinary pathogens; 59% had a dedicated National Reference Laboratory; by February 2022, 15 SSA countries had fully developed NAPs. Thematic performance was 38±12% for awareness creation and training, 18±13% for surveillance, 33±13% for infection prevention and control, 28±23% for optimal antimicrobial use, and 59±12% for multisector and One Health collaboration.
- Burden estimates included 141,918 cholera infections per year in SSA; approximately 1.5 million typhoid cases and 19,900 deaths annually in SSA, accounting for about 17% of global typhoid deaths; 421,600 invasive non-typhoidal Salmonella cases and 66,520 deaths in SSA; and 31% of neonatal sepsis mortalities (690,000) plausibly attributed to antimicrobial-resistant infections.
Methods
- Narrative review of English original articles and reviews retrieved from PubMed and Google Scholar, covering the WHO-Africa region divided into Western, Eastern, Central, and Southern SSA; search terms included antimicrobial resistance, multi-drug resistance, sub-Saharan Africa, surveillance, global action plan, national action plan, and One Health approach; articles published between 2000 and 2022 were considered.
- Pathogens were selected as WHO-GLASS priority pathogens plus Vibrio cholerae; inclusion criteria covered articles on selected pathogens from SSA countries, articles reporting antibiotic resistance rates and genes, and both monomicrobial and polymicrobial studies; exclusions were non-WHO-GLASS pathogens, articles from beyond SSA, conference abstracts, intervention trials, and duplicates.
- The review presents resistance rates from cited studies in tables and discusses NAP implementation; it does not report a pooled meta-analysis.
Limitations
- The paper states that precise burden estimates for resistant K. pneumoniae in SSA are lacking and that available data are generated in referral/research/university hospitals, which do not represent the broad range of healthcare settings; it also states that few A. baumannii reports come from low-income countries, making prevalence estimates difficult.
- The paper states that the paucity of data in SSA on AMR prevalence and antimicrobial use is a major impediment, and it lists NAP implementation challenges including inadequate funding, poor coordination, inadequate surveillance data, poor infrastructure and health systems, staffing shortages, and lack of monitoring and quality assurance systems.
- Evident from the text: as a narrative review using PubMed/Google Scholar and heterogeneous published studies, resistance rates are not pooled or systematically appraised, and many estimates come from single-center or referral-hospital studies that may not be generalizable.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
50 Valid · 5 Not valid · 14 Not checked · 32 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In 2019, sub-Saharan Africa (SSA) had the highest mortality rate (23.5 deaths per 100,000) attributable to AMR compared to other regions.”
- Also stated in: § Impact of Antimicrobial Resistance · plain
“Compared to other Global Burden of Disease study regions, sub-Saharan Africa (SSA) and South Asia had the highest mortalities (23.5 deaths per 100,000 and 21.5 deaths per 100,000, respectively) attributable to AMR.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Abstract
What the sources say
- Partly supportedcites [8] Murray, 2022, Lancet sourceExperimental — accuracy not yet measured
The Results report that sub-Saharan Africa had the highest all-age death rate attributable to AMR in 2019. However, they give 27.3 deaths per 100,000 for western sub-Saharan Africa, the highest of the 21 regions; our copy does not substantiate the claimed 23.5 deaths per 100,000 for sub-Saharan Africa as a whole. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Impact of Antimicrobial Resistance · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Indeed, the rapid emergence of antimicrobial-resistant pathogens is often accelerated by the inappropriate use and overuse of antimicrobial agents, especially antibiotics, in humans, animals, and agriculture/the environment.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Supportedcites [18] Sartelli, 2020, Antibiotics source
Section 2, “Antimicrobial Resistance: A Global Challenge,” says antibiotic use, misuse and abuse in human, animal and environmental sectors drive AMR, and that misuse selects resistant microorganisms. Section 3, “Antimicrobial Resistance in LMICs,” also identifies antibiotic use in agriculture as a challenge. (LLM, conf=0.94)
- Supportedcites [19] Van, 2020, J Glob Antimicrob Resist source
The Introduction identifies repeated antibiotic use in food animals as a significant contributor to antimicrobial resistance and acknowledges the contribution of misuse in humans. Section 4 says widespread antibiotic use in animals accelerates the emergence of resistance and describes the environment as a reservoir and route of spread, including antibiotic use in aquaculture. (LLM, conf=0.90)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In neonatal sepsis, 31% of mortalities (690,000) reported were plausibly attributed to antimicrobial-resistant infections.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Impact of Antimicrobial Resistance
What the sources say
- Supportedcites [11] Li, 2020, Arch Dis Child source
The Introduction reports a previous estimate that 214,000 of 690,000 annual neonatal deaths associated with sepsis (31%) were potentially attributable to antimicrobial resistance. The paper presents this as an estimate from Laxminarayan et al., not a finding of the NeoAMR study. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The study found that the consumption rate increased from 9.8 (9.2-10.5)daily defined doses (DDD) to 14.3 (13.2-15.6)DDD per 1000 population per day.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Supportedcites [26] Browne, 2021, Lancet Planetary Health source
The Results report that global antibiotic consumption rose from 9.8 (95% uncertainty interval 9.2–10.5) to 14.3 (13.2–15.6) defined daily doses per 1000 people per day between 2000 and 2018. These are the figures and period attributed to the study. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A study published in 2021 reported that there was a 46% increase in the global consumption of antimicrobials between 2000 and 2018.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Role of Antimicrobial Use in Increasing Rates of AMR
What the sources say
- Partly supportedcites [26] Browne, 2021, Lancet Planetary Health sourceExperimental — accuracy not yet measured
The Introduction (Added value of this study) reports a 46% increase in global antibiotic consumption since 2000, and the Results give the 2000 and 2018 consumption rates. The study measures antibiotics, not antimicrobials as a whole, so the claim broadens its scope. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
38 more claims · 18 with their cited sources checked
Create a free account to see all 101 claims and to verify the 4 references still open.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 42
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such sparsity is mainly due to insufficient laboratory infrastructure and capacity, scarce or absent microbiological facilities, weak health systems and governance and information systems, and scarce resources.60, 72, 73”
From Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 (2024) · cites this paper as [73]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Carbapenem-Resistant Acinetobacter baumannii
“Out of the 29 countries, only 16 countries reported the detection of A. baumannii within their territories at least once in the last 21 years.”
§ Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? > Carbapenem-Resistant Acinetobacter baumannii
“Accordingly, 11 out of the 29 have no A. baumannii reports at all in the three searched databases.”
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316 · cited 2×
“aeruginosa accounting for 38,100 deaths globally.(151) The prevalence of carbapenem-resistant P.”
BackgroundTacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142 · cited 2×
“aeruginosa as one of the three critical global priority pathogens that require development of new antibiotics.(144) It is estimated that in 2019, antimicrobialresistant P.”
BackgroundAcinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316 · cited 1×
“Acinetobacter baumannii is often implicated in bloodstream, urinary tract, pneumonia, skin and soft tissue infections, and meningitis.(138,139) Owing to its AMR,(140) A.”
BackgroundAntibiotic resistance in the environment
Larsson, D. G. J., & Flach, C.-F. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00649-x · Cited by 3,164
Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30605-4 · Cited by 2,945 · cited 1×
“conducted in the European Union, published in 2019, estimates an annual number of disability-adjusted life-years (DALYs) at 148,727 (131,757–166,361) per 1,000,000 population, infections at 112,782 (103,186–122,006), and attributable deaths at 6810 (6096–7559).(156) While surveillance systems are in place in developed…”
BackgroundAntimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024 · cited 1×
“Infections caused by antimicrobial-resistant pathogens are reported to result in approximately 700,000 deaths globally every year.(3)”
BackgroundManyi-Loh, C., Mamphweli, S., Meyer, E., & Okoh, A. (2018) · Molecules · doi:10.3390/molecules23040795 · Cited by 1,808 · cited 19×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialTroeger, C., Blacker, B. F., Khalil, I. A., Rao, P. C., Cao, S., Zimsen, S. R., Albertson, S. B., Stanaway, J. D., Deshpande, A., Abebe, Z., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30362-1 · Cited by 1,476 · cited 1×
“According to the 2016 Global Burden of Disease (GBD) report, cumulatively these two pathotypes result in 63,523 deaths among all ages annually, throughout the world.(36) Other important E.”
BackgroundThe threat of antimicrobial resistance in developing countries: causes and control strategies
Ayukekbong, J. A., Ntemgwa, M., & Atabe, A. N. (2017) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-017-0208-x · Cited by 1,315 · cited 17×
“Some of the challenges that hinder the implementation of NAPs are: 1) a lack of political commitment, 2) inadequate funding, 3) poor coordination and collaboration between the different sectors, 4) inadequate surveillance Infection and Drug Resistance 2022:15 https://doi.org/10.2147/IDR.S342753 DovePress 3601 Powered…”
BackgroundInfluentialHealth systems financing and the path to universal coverage
Evans, D. B., & Etienne, C. (2010) · Bulletin of the World Health Organization · doi:10.2471/blt.10.078741 · Cited by 1,279
Research works printed but not linked: 6
- 2014, Estimating the Economic Costs of Antimicrobial Resistance
- Webale, 2020, Gastroenterol Hepatol Bed Bench, 13, 238
- Kanteh, 2021, Microb Genom, 7, 000677
- Cornick, 2021, Microb Genom, 7, 000703
- 2022, StatPearls
- Murray, 2022, Lancet, 399, 629, 10.1016/S0140-6736(21)02724-0 · DOI · Paper page
Cited by
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
“60,72,73 In some countries, available data are fragmented, undersampled, or not representative of the broader population.”
Sartorius, B., Gray, A. P., Davis Weaver, N., Robles Aguilar, G., Swetschinski, L. R., Ikuta, K. S., Mestrovic, T., Chung, E., Wool, E. E., Han, C., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(23)00539-9 · Cited by 354
“35,36 Available data in some countries are often fragmented, undersampled, or not necessarily representative of the general underlying population.”
BackgroundGlobal burden of antimicrobial resistance and forecasts to 2050
Kariuki, S. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01885-3 · Cited by 190
Self-citationGlobal Strategies to Combat Antimicrobial Resistance: A One Health Perspective
Mudenda, S., Chabalenge, B., Daka, V., Mfune, R. L., Salachi, K. I., Mohamed, S., Mufwambi, W., Kasanga, M., & Matafwali, S. K. (2023) · Pharmacology & Pharmacy · doi:10.4236/pp.2023.148020 · Cited by 144
Sono, T. M., Yeika, E., Cook, A., Kalungia, A., Opanga, S. A., Acolatse, J. E. E., Sefah, I. A., Jelić, A. G., Campbell, S., Lorenzetti, G., et al. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2259106 · Cited by 95
“For instance in Ghana, there are still concerns due to the lack of available resources and commitment to fully progress their NAP [27], which is similar to other African countries with limited resources and technologies allocated to AMR mitigation [28].”
Background
Metadata
- Authors
- Kariuki, S., Kering, K., Wairimu, C., Onsare, R., & Mbae, C.
- Affiliations
- Kenya Medical Research Institute (KE)
- Corresponding author
- Kariuki, Samuel
- Kering, Kelvin
- Wairimu, Celestine
- Mbae, Cecilia
- Venue
- Infection and Drug Resistance
- Publisher
- Informa UK Limited
- Published
- 2022-07
- Volume
- Volume 15
- Pages
- 3589-3609
- ISSN
- 1178-6973 (ISSN-L)
- PMC
- PMC9273632
- OpenAlex
- W4284678172
- Cited by
- 245
- References
- 189
- Citations by year
- 2026: 72 · 2025: 92 · 2024: 53 · 2023: 27 · 2022: 1
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Infection and Drug Resistance (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc-sa)
- Funders
- Wellcome Trust (215675/Z/19/Z)
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI099525)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Agricultural and Biological Sciences › Food Science › Salmonella and Campylobacter epidemiology
- Keywords
- antimicrobial resistance, antimicrobial resistance surveillance, sub-Saharan Africa, national action plans, One Health, antimicrobial stewardship, infection control, water, sanitation and hygiene, antimicrobial use regulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? https://app.cochat.ai/papers/10.2147/idr.s342753
- The paper
- Kariuki, S., Kering, K., Wairimu, C., Onsare, R., & Mbae, C. (2022). Antimicrobial Resistance Rates and Surveillance in Sub-Saharan Africa: Where Are We Now? Infection and Drug Resistance. https://doi.org/10.2147/idr.s342753
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.